Prostacyclin receptor/thromboxane receptor interactions and cellular responses in human atherothrombotic disease

Current Atherosclerosis Reports

Volumn 11, Issue 3, 2009, Pages 227-235

  Gleim, Scott ^b   Kasza, Zsolt ^b   Martin, Kathleen ^b   Hwa, John ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BERAPROST; CARDIOVASCULAR AGENT; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ILOPROST; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROSTACYCLIN RECEPTOR AGONIST; PROSTANOID; ROFECOXIB; THROMBOXANE; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE RECEPTOR; UNCLASSIFIED DRUG; UNIPROST; VALDECOXIB;

ALLERGY; ALTERNATIVE RNA SPLICING; ARTERY THROMBOSIS; ASTHMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SELECTIVITY; GASTROINTESTINAL SYMPTOM; GENETIC VARIABILITY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INFLAMMATION; KNOCKOUT MOUSE; LOW DRUG DOSE; NONHUMAN; OLIGOMERIZATION; PAIN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; VASODILATATION;

CARDIOVASCULAR DISEASES; HOMEOSTASIS; HUMANS; RECEPTORS, PROSTAGLANDIN; RECEPTORS, THROMBOXANE;

EID: 65449116838     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-009-0035-5     Document Type: Review

References (64)

1. National Heart, Lung and Blood Institute: Morbidity & Mortality: 2007 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: 2007.
2. Bunting S, Gryglewski R, Moncada S, Vane JR: Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 1976, 12:897-913.
3. Cheng Y, Austin SC, Rocca B, et al.: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002, 296:539-541.
4. Grosser T, Fries S, Fitzgerald GA: Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 2006, 116:4-15.
5. Arehart E, Stitham J, Asselbergs FW, et al.: Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: Potential implications for cyclooxygenase-2 inhibition. Circ Res 2008, 102:986-993.
6. Ogawa Y, Tanaka I, Inoue M, et al.: Structural organization and chromosomal assignment of the human prostacyclin receptor gene. Genomics 1995, 27:142-148.
7. Stitham J, Gleim SR, Douville K, et al.: Versatility and differential roles of cysteine residues in human prostacyclin receptor structure and function. J Biol Chem 2006, 281:37227-37236.
8. Stitham J, Stojanovic A, Merenick BL, et al.: The unique ligand-binding pocket for the human prostacyclin receptor. Site-directed mutagenesis and molecular modeling. J Biol Chem 2003, 278:4250-4257.
9. Ruan KH, Wu J, So SP, Jenkins LA: Evidence of the residues involved in ligand recognition in the second extra-cellular loop of the prostacyclin receptor characterized by high resolution 2D NMR techniques. Arch Biochem Biophys 2003, 418:25-33.
10. Stitham J, Stojanovic A, Ross LA, et al.: Clusters of transmembrane residues are critical for human prostacyclin receptor activation. Biochemistry 2004, 43:8974-8986.
11. Stitham J, Stojanovic A, Hwa J: Impaired receptor binding and activation associated with a human prostacyclin receptor polymorphism. J Biol Chem 2002, 277:15439-15444.
12. Hirata M, Hayashi Y, Ushikubi F, et al.: Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 1991, 349:617-620.
13. Nusing R, Hirata M, Kakizuka A, et al.: Characterization and chromosomal mapping of the human thromboxane A2 receptor gene. J Biol Chem 1993, 268:25253-25259.
14. Raychowdhury MK, Yukawa M, Collins LJ, et al.: Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem 1994, 269:19256-19261.
15. Parent JL, Labrecque P, Orsini MJ, Benovic JL: Internalization of the TXA2 receptor alpha and beta isoforms. Role of the differentially spliced cooh terminus in agonist-promoted receptor internalization. J Biol Chem 1999, 274:8941-8948.
16. Hirata T, Ushikubi F, Kakizuka A, et al.: Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 1996, 97:949-956.
17. Wilson SJ, Roche AM, Kostetskaia E, Smyth EM: Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation. J Biol Chem 2004, 279:53036-53047.
18. Wilson SJ, Dowling JK, Zhao L, et al.: Regulation of thromboxane receptor trafficking through the prostacyclin receptor in vascular smooth muscle cells: Role of receptor heterodimerization. Arterioscler Thromb Vasc Biol 2007, 27:290-296.
19. Wise H, Jones RL: Prostacyclin and Its Receptors. New York: Plenum Publishers; 2000:310.
20. Moncada S, Gryglewski R, Bunting S, Vane JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976, 263:663-665.
21. Pola R, Gaetani E, Flex A, et al.: Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: A possible role for peroxisome proliferator-activated receptors. J Mol Cell Cardiol 2004, 36:363-370.
22. Shenker A, Goldsmith P, Unson CG, Spiegel AM: The G protein coupled to the thromboxane A2 receptor in human platelets is a member of the novel Gq family. J Biol Chem 1991, 266:9309-9313.
23. Hunt JA, Merritt JE, MacDermot J, Keen M: Characterization of the thromboxane receptor mediating prostacyclin release from cultured endothelial cells. Biochem Pharmacol 1992, 43:1747-1752.
24. Zhang W, Zhang Y, Edvinsson L, Xu CB: Transcriptional down-regulation of thromboxane A2 receptor expression via activation of MAPK ERK1/2, p38/ NF-kB pathways. J Vasc Res 2009, 46:162-174.
25. Milling Smith OP, Battersby S, Sales KJ, et al.: Prostacyclin receptor up-regulates the expression of angiogenic genes in human endometrium via cross talk with epidermal growth factor receptor and the extracellular signaling receptor kinase 1/2 pathway. Endocrinology 2006, 147:1697-1705.
26. Meyer-Kirchrath J, Debey S, Glandorff C, et al.: Gene expression profile of the Gs-coupled prostacyclin receptor in human vascular smooth muscle cells. Biochem Pharmacol 2004, 67:757-765.
27. Walsh M, Kinsella BT: Regulation of the human prostanoid TP [alpha] and TP [beta] receptor isoforms mediated through activation of the EP1 and IP receptors. Br J Pharmacol 2000, 131:601-609.
28. Hansson GK, Libby P: The immune reAponse in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6:508-519.
29. Cipollone F, Prontera C, Pini B, et al.: Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 2001, 104:921-927.
30. Vane JR: Nobel lecture, 8th December 1982. Adventures and excursions in bioassay: The stepping stones to prostacyclin. Br J Pharmacol 1983, 79:821-838.
31. Della Bella S, Molteni M, Mocellin C, et al.: Novel mode of action of iloprost: In vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Other Lipid Mediat 2001, 65:73-83.
32. Pomerantz KB, Fleisher LN, Tall AR, Cannon PJ: Enrichment of endothelial cell arachidonate by lipid transfer from high density lipoproteins: relationship to prostaglandin I2 synthesis. J Lipid Res 1985, 26:1269-1276.
33. Blindt R, Bosserhoff AK, vom Dahl J, et al.: Activation of IP and EP(3) receptors alters cAMP-dependent cell migration. Eur J Pharmacol 2002, 444:31-37.
34. Owens GK, Kumar MS, Wamhoff BR: Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004, 84:767-801.
35. Fetalvero KM, Shyu M, Nomikos AP, et al.: The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am J Physiol Heart Circ Physiol 2006, 290:H1337-1346.
36. O'Brien ER, Alpers CE, Stewart DK, et al.: Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy. Circ Res 1993, 73:223-231.
37. Wilcox JN: Analysis of local gene expression in human atherosclerotic plaques. J Vasc Surg 1992, 15:913-916.
38. Campbell GR, Campbell JH, Manderson JA, et al.: Arterial smooth muscle. A multifunctional mesenchymal cell. Arch Pathol Lab Med 1988, 112:977-986.
39. Kobayashi T, Tahara Y, Matsumoto M, et al.: Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apo-E deficient mice. J Clin Invest 2004, 114:784-794.
40. Yokoyama C, Yabuki T, Shimonishi M, et al.: Prostacyclindeficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 2002, 106:2397-2403.
41. Egan KM, Lawson JA, Fries S, et al.: COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004, 306:1954-1957.
42. Egan KM, Wang M, Lucitt MB, et al.: Cyclooxygenases, thromboxane, and atherosclerosis: Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005, 111:334-342.
43. McClelland S, Gawaz M, Kennerknecht E, et al.: Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse. Atherosclerosis 2009, 202:84-91.
44. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C: Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005, 353:2373-2383.
45. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-1528.
46. Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-1102.
47. Nussmeier NA, Whelton AA, Brown MT, et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352:1081-1091.
48. Stitham J, Arehart EJ, Gleim SR, et al.: Arginine (CGC) codon targeting in the human prostacyclin receptor gene (PTGIR) and G-protein coupled receptors (GPCR). Gene 2007, 396:180-187.
49. Patrignani P, Di Febbo C, Tacconelli S, et al.: Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: A clinical biomarker study. Pharmacogenet Genomics 2008, 18:611-620.
50. Kim SH, Choi JH, Park HS, et al.: Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma. Clin Exp Allergy 2005, 35:585-590.
51. Tanaka K, Roberts MH, Yamamoto N, et al.: Genetic variants of the receptors for thromboxane A2 and IL-4 in atopic dermatitis. Biochem Biophys Res Commun 2002, 292:776-780.
52. Hirata T, Kakizuka A, Ushikubi F, et al.: Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994, 94:1662-1667.
53. Tanaka K, Roberts MH, Yamamoto N, et al.: Genetic variants of the receptors for thromboxane A2 and IL-4 in atopic dermatitis. Biochem Biophys Res Commun 2002, 292:776-780.
54. Fujiwara T, Ikeda M, Esumi K, et al.: Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity. Pharmacogenomics J 2007, 7:395-403.
55. Unoki M, Furata S, Onouchi Y, et al.: Association studies of 33 single nucleotide polymorphisms (SNPs) in 29 candidate genes for bronchial asthma: Positive association a T924C polymorphism in the thromboxane A2 receptor gene. Hum Genet 2000, 106:440-446.
56. Hong SJ, Lee SY, Kim HB, et al.: IL-5 and thromboxane A2 receptor gene polymorphisms are associated with decreased pulmonary function in Korean children with atopic asthma. J Allergy Clin Immunol 2005, 115:758-763.
57. Audoly LP, Rocca B, Fabre JE, et al.: Cardiovascular responses to the isoprostanes iPF2{alpha}-III and iPE2-III are mediated via the thromboxane A2 receptor in vivo. Circulation 2000, 101:2833-2840.
58. Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351:1425-1436.
59. Sitbon O, Humbert M, Nunes H, et al.: Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002, 40:780-788.
60. Simonneau G, Barst RJ, Galie N, et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A doubleblind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800-804.
61. Galie N, Humbert M, Vachiery JL, et al.: Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002, 39:1496-1502.
62. Olschewski H, Simonneau G, Galie N, et al.: Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329.
63. Hoeper MM, Schwarze M, Ehlerding S, et al.: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000, 342:1866-1870.
64. Guerrero JA, Navarro-Nunez L, Lozano ML, et al.: Flavonoids inhibit the platelet TxA2 signalling pathway and antagonize TxA2 receptors (TP) in platelets and smooth muscle cells. Br J Clin Pharmacol 2007, 64:133-144.